The Restore Study – a clinical trial for gay and bisexual men with prostate cancer who wish to restore their erections and/or urine control. Sign up for more information at: malecare.org/restore
An NIH/NCI funded clinical trial conducted by researchers from Malecare and the University of Minnesota. YOU CAN LIVE ANYWHERE IN THE USA TO PARTICIPATE. The "materials" are sent to you and follow-up is done remotely.
Doctors don’t know what will work for gay and bisexual with prostate cancer, because there are no evidence based studies. Our study will change that.
Three ways we’re improving prostate cancer treatment for gay and bisexual men:
1. Prostate cancer is the second most common cancer among gay, bisexual, and other men who have sex with men (MsM) with documented disparities, yet it suffers a poverty of research. There are 614 studies focused on heterosexual men but their findings may not generalize to gay and bisexual men with prostate cancer. We have created an evidence-based study to understand best practices with the gay and bisexual patients.
2. We are studying a new MsM focused rehabilitation program including both urinary and sexual function.
3. Most prostate cancer studies have focused on men recently treated for prostate cancer. We’re studying men from a broad treatment timeline.
Our randomized control trial will identify whether a structured rehabilitation program is effective in addressing the major sexual and urinary problems caused by prostate cancer treatment. We hope our study will improve sexual and urinary rehabilitation for MsM with prostate cancer by creating an evidence based set of interventions.
The RESTORE study is open to United States residents who are Gay, Bisexual or other men who have sex with men and have been treated for prostate cancer. These men are having difficulty with urinary and or sexual functioning.
If you match these criteria and would consider being part of the study, please sign up at malecare.org/restore . We’ll be in touch with you by late April, 2019. Please help by spreading word about this first-of-its-kind clinical trial for our community.